Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors
NCT05628077 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200
Last updated 2023-03-07
Summary
We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence
Conditions
- Breast Cancer
- Aromatase Inhibitors
- Endocrine Therapy
- Pain
- Anxiety
- Depression
- Sleep
Interventions
- OTHER
-
No intervention
No intervention
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-30
- Primary Completion
- 2023-03-20
- Completion
- 2023-04-20
Countries
- China
Study Locations
More Related Trials
-
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
NCT01814397 ·Status: COMPLETED
-
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
NCT01758146 ·Status: UNKNOWN ·Phase: PHASE3
-
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
NCT01080170 ·Status: COMPLETED
-
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
NCT01983995 ·Status: COMPLETED
-
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
NCT02769104 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062 ·Status: RECRUITING ·Phase: PHASE3
-
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
NCT00692289 ·Status: COMPLETED
-
Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment
NCT01144572 ·Status: COMPLETED
-
ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients
NCT06606535 ·Status: RECRUITING
-
Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women
NCT02480218 ·Status: COMPLETED
-
Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors
NCT06214598 ·Status: RECRUITING ·Phase: NA
-
Adherence to Aromatase Inhibitors: The Role of Partners
NCT02753985 ·Status: COMPLETED
-
Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer
NCT04693338 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
NCT03045653 ·Status: COMPLETED ·Phase: PHASE2
-
Tamoxifen in Treating Women With Breast Cancer
NCT00003678 ·Status: UNKNOWN ·Phase: PHASE3
-
Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors
NCT06728579 ·Status: RECRUITING ·Phase: PHASE2
-
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
NCT02161315 ·Status: UNKNOWN
-
Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
NCT00681928 ·Status: COMPLETED
-
Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT07067307 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer
NCT00641303 ·Status: COMPLETED ·Phase: NA
-
Breast Cancer & Antiestrogenic Therapy & Brain
NCT06346457 ·Status: NOT_YET_RECRUITING
-
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
NCT06781762 ·Status: RECRUITING
-
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
NCT02914158 ·Status: RECRUITING ·Phase: PHASE3
-
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
NCT01612871 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
NCT05801705 ·Status: UNKNOWN